Prognostic Impact of Cardiorenal Anemia Syndrome in Patients With Atrial Functional Mitral Regurgitation Authors: Madoka Sano, Taiji Okada, Tomohiro Kaneko, Masashi Amano, Yukio Sato, Yohei Ohno, Masaru Obokata, Kimi Sato, Kojiro Morita, Tomoko Machino-Ohtsuka, Yukio Abe, Yutaka Furukawa, Nobuyuki Kagiyama, on behalf of the REVEAL-AFMR Study Group Published: 2026 ABSTRACT BackgroundAtrial functional mitral regurgitation (AFMR) frequently affects older patients, but the high-risk patient subgroups requiring careful follow-up and targeted therapy remain unclear. AFMR causes venous congestion and reduced forward cardiac output, which may accelerate chronic kidney disease (CKD) and anemia. Cardiorenal anemia syndrome (CRAS) is a known prognostic factor in heart failure (HF), and AFMR-specific hemodynamic disturbances may amplify its consequences. The aim of this study was to evaluate the impact of CRAS on cardiovascular outcomes in AFMR.Methods and ResultsThe multicenter, retrospective, observational REVEAL-AFMR registry enrolled patients with moderate-to-severe AFMR in 2019. Patients were stratified into CRAS and non-CRAS groups based on the simultaneous presence of HF, CKD, and anemia. The primary outcome was a composite of all-cause death and HF hospitalization. Among the 957 patients analyzed, 243 had CRAS. Over a median follow-up period of 1,043 days, 279 composite events occurred. Kaplan–Meier analysis demonstrated a higher incidence of composite outcomes in the CRAS group across all AFMR severities. Multivariable Cox regression analysis identified CRAS, older age, lower body mass index, and lower systolic blood pressure as independent predictors of cardiovascular events.ConclusionsCRAS is common in AFMR and may be independently associated with an increased risk of future cardiovascular events. Assessment of CRAS may be helpful for risk stratification and management in this population. Central Figure.The REVEAL-AFMR registry was an observational, multicenter, retrospective registry from January to December 2019, enrolling patients with moderate to severe atrial functional mitral regurgitation (AFMR). Cardiorenal anemia syndrome (CRAS) was present in 25.4% of patients with AFMR and significantly associated with worse cardiovascular outcomes (hazard ratio (HR), 2.36; 95% confidence interval (CI), 1.80–3.09; P<0.001). ACD, all-cause death; CKD, chronic kidney disease; HF, heart failure. The REVEAL-AFMR registry was an observational, multicenter, retrospective registry from January to December 2019, enrolling patients with moderate to severe atrial functional mitral regurgitation (AFMR). Cardiorenal anemia syndrome (CRAS) was present in 25.4% of patients with AFMR and significantly associated with worse cardiovascular outcomes (hazard ratio (HR), 2.36; 95% confidence interval (CI), 1.80–3.09; P<0.001). ACD, all-cause death; CKD, chronic kidney disease; HF, heart failure. The incidence of heart failure (HF), atrial fibrillation (AF), and valvular heart disease is increasing in aging societies.1,2 Atrial functional mitral regurgitation (AFMR) is a common complication in patients with HF, and previous studies have suggested its association with worse clinical outcomes, including HF hospitalization, cardiovascular death, and all-cause death (ACD).3,4 However, the high-risk subgroups within the AFMR population have not been clearly identified. Patients with AFMR are typically older and have multiple comorbidities that compromise prognosis. Among these comorbidities, chronic kidney disease (CKD) and anemia frequently coexist, and each has been independently associated with adverse cardiovascular events. CKD is a well-known risk factor for HF progression and is associated with poorer outcomes in other cardiovascular diseases.5,6 Anemia, caused by iron deficiency, inflammation, renal insufficiency, and other factors, reduces oxygen delivery, increases cardiac oxygen demand, and promotes left ventricular remodeling, thereby worsening HF symptoms and prognosis.7,8 The coexistence of HF, CKD, and anemia may have a synergistic effect, amplifying the risk of cardiovascular events, a condition termed cardiorenal anemia syndrome (CRAS).9,10 Although CRAS strongly predicts adverse cardiovascular events in various populations with HF, its specific impact on patients with AFMR remains unclear. However, there are plausible pathophysiological reasons to hypothesize that CRAS may have a particularly detrimental impact in AFMR. In patients with AFMR, chronic left atrial (LA) pressure elevation and volume overload impose backward pressure on the pulmonary and renal venous systems, leading to renal venous congestion and reduced effective renal perfusion.11,12 We hypothesized that these hemodynamic changes may accelerate CKD progression and contribute to the development and worsening of anemia, even in the absence of overt left ventricular failure. AFMR also reduces forward cardiac output and increases the cardiac workload, further compromising oxygen delivery. Therefore, anemia may exert a disproportionately negative impact in this setting. These pathophysiological disturbances suggest that CRAS may exert particularly harmful effects in patients with AFMR. Despite these considerations, neither the prevalence of CRAS in AFMR nor its prognostic implications has been systematically evaluated. Furthermore, the characteristics of high-risk subgroups within the AFMR population itself remain poorly understood, making it difficult to identify which patients might benefit most from targeted treatment strategies. Given that each component of CRAS is potentially modifiable through optimized HF care, renal management, and anemia-targeted therapies, identifying whether CRAS confers incremental risk in AFMR is of significant clinical relevance. Improved understanding of CRAS in this population could help refine risk stratification, guide integrated management strategies, and ultimately contribute to better outcomes. Therefore, we aimed to analyze a large AFMR cohort to determine the prevalence of CRAS and examine its combined impact on cardiovascular outcomes, to identify modifiable prognostic factors. Methods Study Design This was a secondary analysis of the Real-World Observational Study for Investigating the Prevalence and Therapeutic Options for Atrial Functional Mitral Regurgitation (REVEAL-AFMR) registry. The details of the main study design and primary results have been published previously.13 In brief, it was a multicenter, retrospective, observational cohort study conducted in Japan at 26 participating institutions. All transthoracic echocardiography procedures performed from January to December 2019 were reviewed to include patients aged ≥20 years with moderate or severe AFMR, defined by preserved left ventricular ejection fraction (≥50%) without regional wall motion abnormality, LA dilatation (LA volume index (LAVI) ≥38 mL/m2 for men, ≥41 mL/m2 for women, based on reported normal values in the Japanese population),14 and absence of degenerative valvular changes. The exclusion criteria were: trivial-to-mild mitral regurgitation (MR); degenerative MR or post-mitral valve surgery; absence of LA dilatation; other etiologies, including systolic anterior motion; or acute decompensated HF. Patients without hemoglobin and/or estimated glomerular filtration rate (eGFR) data and those undergoing dialysis were also excluded. Patients were stratified based on whether they met the criteria for CRAS, defined as the simultaneous presence of HF, CKD, and anemia. HF was defined as New York Heart Association (NYHA) class II or higher or a documented history of HF, reflecting the symptomatic criteria highlighted in current clinical guidelines.15 CKD was defined as eGFR <60 mL/min/1.73 m2, calculated using the CKD-EPI Creatinine Equation.16 Anemia was defined as hemoglobin <13 g/dL in men and <12 g/dL in women.17 Blood test data were evaluated at the time of enrollment. Treatment strategies were based on relevant Japanese clinical guidelines, including those for HF and valvular heart disease, and were determined by each participating center at the discretion of the treating physicians. The primary outcome was a composite of ACD and hospitalization for HF. The secondary outcomes were ACD and hospitalization for HF, analyzed separately. This study was registered in the University Hospital Medical Information Network Clinical Trials Registry and the Japanese Clinical Trial Registry (registration number: UMIN000046146) and approved by the Institutional Review Board of Juntendo University and each participating institution, including Kobe City Medical Center General Hospital (approval no. kzh250408). The investigation conformed to the principles outlined in the Declaration of Helsinki and adhered to the Strengthening the Reporting of Observational Studies in Epidemiology reporting guidelines. All enrolled individuals were informed of the study details and reassured that they could withdraw at any time. Written informed consent was waived because of the observational and retrospective nature of the study, in accordance with the ethical guidelines for medical and biological research involving human participants in Japan. Statistical Analysis Categorical variables are expressed as numbers and percentages and compared using the chi-squared or Fisher’s exact test, as appropriate. Continuous variables are expressed as medians with interquartile ranges (IQRs) or means with standard deviations and were compared using the Wilcoxon rank-sum test or Student’s t-test, depending on their distribution. Cumulative incidences were estimated using the Kaplan–Meier method, and differences among groups were assessed using a log-rank test. Multivariable Cox proportional hazards models were used to assess the primary and secondary outcomes. The multivariable analysis was adjusted for age, sex, CRAS, body mass index (BMI), systolic blood pressure, severity of MR, and EuroSCORE II, based on baseline data at the time of cohort entry. These covariates have been established as prognostic factors of cardiovascular diseases and used in previous analyses of the REVEAL-AFMR registry.13,18–20 To evaluate the combined and interactive effects of HF, CKD, and anemia, additional Cox models were used to examine each component and their interactions, testing whether CRAS represented a synergistic risk factor beyond its individual components. All P values were two-sided, with <0.05 indicating statistical significance. Missing values were not imputed and were excluded from the analysis. All statistical analyses were performed using JMP software (version 18.2.2, SAS Institute Inc., Cary, NC, USA). Results Characteristics of the Study Population Figure 1 shows the patient selection flowchart. Of the 177,235 patients who underwent transthoracic echocardiography, 8,867 had moderate or severe MR, and 1,007 were diagnosed with AFMR. After excluding 21 patients with missing hemoglobin or eGFR data and 29 patients undergoing dialysis, 957 patients were included in the analysis. Of them, 705 (73.7%) had HF, 400 (41.8%) had CKD, and 546 (57.1%) had anemia (Central Figure). CRAS, defined as the coexistence of all 3 conditions, was present in 243 (25.4%) patients. The prevalence of CRAS and its individual components stratified by MR severity is presented in Figure 2. The prevalence of CRAS and its components increased as MR severity increased. The median follow-up period was 1,043 (IQR, 726–1,174) days. Figure 1.Study flowchart. The REVEAL-AFMR registry enrolled patients with moderate-to-severe AFMR. A total of 957 patients were included in the analysis, of whom 243 (25.4%) were diagnosed with CRAS. AFMR, atrial functional mitral regurgitation; CKD, chronic kidney disease; CRAS, cardiorenal anemia syndrome; HF, heart failure; LA, left atrial; MR, mitral regurgitation; MV, mitral valve; REVEAL-AFMR, Real-World Observational Study for Investigating the Prevalence and Therapeutic Options for Atrial Functional Mitral Regurgitation; SAM, systolic anterior motion. Figure 2.Prevalence of CRAS and its components stratified by MR severity. CKD, chronic kidney disease; CRAS, cardiorenal anemia syndrome; HF, heart failure; MR, mitral regurgitation. Study flowchart. The REVEAL-AFMR registry enrolled patients with moderate-to-severe AFMR. A total of 957 patients were included in the analysis, of whom 243 (25.4%) were diagnosed with CRAS. AFMR, atrial functional mitral regurgitation; CKD, chronic kidney disease; CRAS, cardiorenal anemia syndrome; HF, heart failure; LA, left atrial; MR, mitral regurgitation; MV, mitral valve; REVEAL-AFMR, Real-World Observational Study for Investigating the Prevalence and Therapeutic Options for Atrial Functional Mitral Regurgitation; SAM, systolic anterior motion. Prevalence of CRAS and its components stratified by MR severity. CKD, chronic kidney disease; CRAS, cardiorenal anemia syndrome; HF, heart failure; MR, mitral regurgitation. Patients’ baseline characteristics, classified based on the presence of CRAS, are presented in Table 1. Patient characteristics classified into 4 groups according to the number of CRAS components are presented in the Supplementary Table. The mean age was 77.8±9.5 years, and 424 (44.3%) patients were men. Compared with patients without CRAS, those with CRAS were older and had a higher prevalence of NYHA III or IV, pacemaker implantation, and coronary artery disease. On echocardiography, patients with CRAS had a larger LAVI and a higher prevalence of severe MR and tricuspid regurgitation (TR) compared with those without CRAS. Diuretics were used more frequently in patients with CRAS than in those without. Echocardiographic values stratified by MR severity are presented in Table 2. Table 1.Patient Characteristics Stratified by Presence of CRAS nAll (n=957)CRAS − (n=714)CRAS + (n=243)P valueAge, mean±SD, years95777.8±9.576.4±9.781.9±7.3<0.001Male, no. (%)957424 (44.3%)315 (44.1%)109 (44.9%)0.841Clinical data, mean±SD Body surface area, m29521.53±0.191.54±0.191.50±0.190.003 BMI, kg/m295222.0±3.422.1±3.521.8±3.10.194 SBP, mmHg905126.5±19.7127.1±19.0125.0±21.60.078 Heart rate, /min94672.5±16.672.8±15.871.4±18.80.085Laboratory data, mean±SD White blood cell, /μL9575,691±2,2365,734±2,1385,567±2,5000.010 Hemoglobin, g/dL95711.9±2.012.4±1.810.1±1.5<0.001 Hematocrit, %95736.1±5.737.7±5.231.3±4.4<0.001 MCHC, %95732.8±1.132.9±1.132.3±1.2<0.001 Platelet, ×104/μL95718.1±8.018.9±7.915.9±7.7<0.001 BUN, mg/dL94723.2±11.819.8±8.1033.2±15.0<0.001 Creatinine, mg/dL9571.1±0.80.9±0.61.6±1.0<0.001 eGFR, mL/min/1.73 m295764.6±23.373.0±19.740.1±13.6<0.001 BNP, median (IQR), pg/mL527194 [113–360]171 [103–302]286 [140–507]<0.001 NT-proBNP, median (IQR), pg/mL6241,251 [546–2,544]903 [458–1,845]2,870 [1,395–4,984]<0.001Comorbidities, n (%) NYHA (III or IV)957104 (10.9%)54 (7.6%)50 (10.6%)<0.001 Current smoker92769 (7.4%)53 (7.7%)16 (6.7%)0.594 Hypertension957807 (84.3%)598 (83.8%)209 (86.0%)0.404 Dyslipidemia957449 (46.9%)333 (46.6%)116 (47.7%)0.767 Prior HF957359 (37.5%)204 (28.6%)155 (63.8%)<0.001 Prior HF admission957258 (27.0)137 (19.2%)121 (49.8%)<0.001 Pacemaker implantation95783 (8.7%)50 (7.0%)33 (13.6%)0.002 Coronary artery disease957129 (13.5%)81 (11.3%)48 (19.8%)0.001 Diabetes957140 (14.6%)99 (13.9%)41 (16.9%)0.252Type of AF, n (%) Paroxysmal957134 (14.0%)103 (14.4%)31 (12.8%)0.480 Persistent36 (3.8%)26 (3.6%)10 (4.1%) Permanent607 (63.4%)444 (62.2%)163 (67.1%) Sinus rhythm180 (18.8%)141 (19.8%)39 (16.1%) AF duration, median (IQR), months67772 [17–144]63 [14–144]72 [24–144]0.47 EuroSCOREII, median (IQR), %9572.3 [1.4–4.1]1.9 [1.2–3.1]4.2 [2.8–7.2]<0.001Medications, n (%) Loop diuretics957527 (55.1%)331 (46.4%)196 (80.7%)<0.001 Tolvaptan95793 (9.7%)44 (6.2%)49 (20.2%)<0.001 ACE-I or ARB957438 (45.8%)319 (44.7%)119 (49.0%)0.246 β-blocker957478 (50.0%)357 (50.0%)121 (49.8%)0.956 MRA957260 (27.2%)170 (23.8%)90 (37.0%)<0.001 Anticoagulation drugs957686 (71.7%)513 (71.9%)173 (71.2%)0.845Echocardiographic data, mean±SD LVDd, mm95748.9±6.848.7±6.749.8±7.00.032 LVDs, mm95732.3±5.632.1±5.532.8±5.70.081 LVEDV, mL95797.2±35.796.2±35.5100.2±36.10.138 LVESV, mL95737.5±15.737.1±15.538.7±16.20.192 LVEF, %95761.7±5.961.8±5.861.5±6.30.390 LAVI, mL/m289594.5±57.789.9±55.2108.0±63.0<0.001 TR velocity, m/s9162.8±0.52.7±0.42.9±0.5<0.001 Severe TR, no. (%)957140 (14.6%)86 (12.0%)54 (22.2%)<0.001MR grade, n (%) Moderate957686 (71.7%)538 (75.4%)148 (60.9%)<0.001 Moderate-to-severe140 (14.6%)95 (13.3%)45 (18.5%) Severe131 (13.7%)81 (11.3%)50 (20.6%)ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CRAS, cardiorenal anemia syndrome; eGFR, estimated glomerular filtration rate; HF, heart failure; IQR, interquartile range; LAVI, left atrial volume index; LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MCHC, mean corpuscular hemoglobin concentration; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation; TR, tricuspid regurgitation. Table 2.Echocardiographic Data Stratified by MR Severity Moderate (n=686)Moderate-severe (n=140)Severe (n=131)P valueLVDd, mm47.9±6.549.5±6.953.6±6.9<0.001LVDs, mm31.6±5.432.6±5.735.2±5.3<0.001LVEDV, mL92.9±33.798.8±34.9118.2±39.0<0.001LVESV, mL35.9±38.238.2±15.645.3±15.7<0.001LVEF, %61.8±6.061.4±5.361.5±6.20.774LAVI, mL/m282.6±44.4104.5±51.9147.4±87.6<0.001TR velocity, m/s2.7±0.52.8±0.42.9±0.5<0.001Severe TR, no. (%)79 (11.5%)20 (14.3%)41 (31.3%)<0.001Abbreviations as in Table 1. Table 1.Patient Characteristics Stratified by Presence of CRAS nAll (n=957)CRAS − (n=714)CRAS + (n=243)P valueAge, mean±SD, years95777.8±9.576.4±9.781.9±7.3<0.001Male, no. (%)957424 (44.3%)315 (44.1%)109 (44.9%)0.841Clinical data, mean±SD Body surface area, m29521.53±0.191.54±0.191.50±0.190.003 BMI, kg/m295222.0±3.422.1±3.521.8±3.10.194 SBP, mmHg905126.5±19.7127.1±19.0125.0±21.60.078 Heart rate, /min94672.5±16.672.8±15.871.4±18.80.085Laboratory data, mean±SD White blood cell, /μL9575,691±2,2365,734±2,1385,567±2,5000.010 Hemoglobin, g/dL95711.9±2.012.4±1.810.1±1.5<0.001 Hematocrit, %95736.1±5.737.7±5.231.3±4.4<0.001 MCHC, %95732.8±1.132.9±1.132.3±1.2<0.001 Platelet, ×104/μL95718.1±8.018.9±7.915.9±7.7<0.001 BUN, mg/dL94723.2±11.819.8±8.1033.2±15.0<0.001 Creatinine, mg/dL9571.1±0.80.9±0.61.6±1.0<0.001 eGFR, mL/min/1.73 m295764.6±23.373.0±19.740.1±13.6<0.001 BNP, median (IQR), pg/mL527194 [113–360]171 [103–302]286 [140–507]<0.001 NT-proBNP, median (IQR), pg/mL6241,251 [546–2,544]903 [458–1,845]2,870 [1,395–4,984]<0.001Comorbidities, n (%) NYHA (III or IV)957104 (10.9%)54 (7.6%)50 (10.6%)<0.001 Current smoker92769 (7.4%)53 (7.7%)16 (6.7%)0.594 Hypertension957807 (84.3%)598 (83.8%)209 (86.0%)0.404 Dyslipidemia957449 (46.9%)333 (46.6%)116 (47.7%)0.767 Prior HF957359 (37.5%)204 (28.6%)155 (63.8%)<0.001 Prior HF admission957258 (27.0)137 (19.2%)121 (49.8%)<0.001 Pacemaker implantation95783 (8.7%)50 (7.0%)33 (13.6%)0.002 Coronary artery disease957129 (13.5%)81 (11.3%)48 (19.8%)0.001 Diabetes957140 (14.6%)99 (13.9%)41 (16.9%)0.252Type of AF, n (%) Paroxysmal957134 (14.0%)103 (14.4%)31 (12.8%)0.480 Persistent36 (3.8%)26 (3.6%)10 (4.1%) Permanent607 (63.4%)444 (62.2%)163 (67.1%) Sinus rhythm180 (18.8%)141 (19.8%)39 (16.1%) AF duration, median (IQR), months67772 [17–144]63 [14–144]72 [24–144]0.47 EuroSCOREII, median (IQR), %9572.3 [1.4–4.1]1.9 [1.2–3.1]4.2 [2.8–7.2]<0.001Medications, n (%) Loop diuretics957527 (55.1%)331 (46.4%)196 (80.7%)<0.001 Tolvaptan95793 (9.7%)44 (6.2%)49 (20.2%)<0.001 ACE-I or ARB957438 (45.8%)319 (44.7%)119 (49.0%)0.246 β-blocker957478 (50.0%)357 (50.0%)121 (49.8%)0.956 MRA957260 (27.2%)170 (23.8%)90 (37.0%)<0.001 Anticoagulation drugs957686 (71.7%)513 (71.9%)173 (71.2%)0.845Echocardiographic data, mean±SD LVDd, mm95748.9±6.848.7±6.749.8±7.00.032 LVDs, mm95732.3±5.632.1±5.532.8±5.70.081 LVEDV, mL95797.2±35.796.2±35.5100.2±36.10.138 LVESV, mL95737.5±15.737.1±15.538.7±16.20.192 LVEF, %95761.7±5.961.8±5.861.5±6.30.390 LAVI, mL/m289594.5±57.789.9±55.2108.0±63.0<0.001 TR velocity, m/s9162.8±0.52.7±0.42.9±0.5<0.001 Severe TR, no. (%)957140 (14.6%)86 (12.0%)54 (22.2%)<0.001MR grade, n (%) Moderate957686 (71.7%)538 (75.4%)148 (60.9%)<0.001 Moderate-to-severe140 (14.6%)95 (13.3%)45 (18.5%) Severe131 (13.7%)81 (11.3%)50 (20.6%)ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CRAS, cardiorenal anemia syndrome; eGFR, estimated glomerular filtration rate; HF, heart failure; IQR, interquartile range; LAVI, left atrial volume index; LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MCHC, mean corpuscular hemoglobin concentration; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation; TR, tricuspid regurgitation. Patient Characteristics Stratified by Presence of CRAS ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; CRAS, cardiorenal anemia syndrome; eGFR, estimated glomerular filtration rate; HF, heart failure; IQR, interquartile range; LAVI, left atrial volume index; LVDd, left ventricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MCHC, mean corpuscular hemoglobin concentration; MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation; TR, tricuspid regurgitation. Table 2.Echocardiographic Data Stratified by MR Severity Moderate (n=686)Moderate-severe (n=140)Severe (n=131)P valueLVDd, mm47.9±6.549.5±6.953.6±6.9<0.001LVDs, mm31.6±5.432.6±5.735.2±5.3<0.001LVEDV, mL92.9±33.798.8±34.9118.2±39.0<0.001LVESV, mL35.9±38.238.2±15.645.3±15.7<0.001LVEF, %61.8±6.061.4±5.361.5±6.20.774LAVI, mL/m282.6±44.4104.5±51.9147.4±87.6<0.001TR velocity, m/s2.7±0.52.8±0.42.9±0.5<0.001Severe TR, no. (%)79 (11.5%)20 (14.3%)41 (31.3%)<0.001Abbreviations as in Table 1. Echocardiographic Data Stratified by MR Severity Abbreviations as in Table 1. Association Between CRAS and Cardiovascular Outcomes During the follow-up period, 279 composite cardiovascular events (184 ACD and 139 HF hospitalizations) occurred. The Kaplan–Meier curve demonstrated that the cumulative incidence rate of composite cardiovascular events was higher in patients with CRAS than in those without CRAS (1-year event rates: 23.7% vs. 9.3%; log-rank, P<0.001) (Figure 3). Separately, ACD (1-year event rate: 14.7% vs. 5.3%; log-rank, P<0.001) and HF hospitalization (1-year event rate, 13.2% vs. 4.6%; log-rank, P<0.001) were more frequent in patients with CRAS than in those without. Furthermore, stratification according to the number of CRAS components revealed that the coexistence of all 3 components was associated with a significantly higher incidence of cardiovascular events (log-rank test, P<0.001) (Supplementary Figure 1). Similarly, individual evaluation of HF, CKD, and anemia showed that each condition was associated with increased composite event incidence (Supplementary Figure 2). Analysis according to MR severity revealed similar CRAS-related risks across the moderate (n=686, 71.7%), moderate-to-severe (n=140, 14.6%), and severe MR (n=131, 13.7%) subgroups (Figure 4A). Similarly, CRAS predicted higher event rates regardless of treatment strategy: medical therapy (n=820, 85.7%), surgical repair (n=107, 11.2%), or transcatheter mitral valve repair (n=30, 3.1%) (Figure 4B). Figure 3.Cumulative incidences of cardiovascular events in patients with/without CRAS. ACD, all-cause death; CRAS, cardiorenal anemia syndrome; HF, heart failure. Figure 4.Cumulative incidences of cardiovascular events in patients with/without CRAS stratified by (A) MR severity and (B) treatment for MR. The cumulative incidence of cardiovascular events was higher in patients with CRAS across all degrees of MR severity than in those without, regardless of whether the patients underwent medical therapy, transcatheter mitral valve repair, or mitral valve surgery. CRAS, cardiorenal anemia syndrome; MR, mitral regurgitation. Cumulative incidences of cardiovascular events in patients with/without CRAS. ACD, all-cause death; CRAS, cardiorenal anemia syndrome; HF, heart failure. Cumulative incidences of cardiovascular events in patients with/without CRAS stratified by (A) MR severity and (B) treatment for MR. The cumulative incidence of cardiovascular events was higher in patients with CRAS across all degrees of MR severity than in those without, regardless of whether the patients underwent medical therapy, transcatheter mitral valve repair, or mitral valve surgery. CRAS, cardiorenal anemia syndrome; MR, mitral regurgitation. In the multivariable Cox proportional hazards models, CRAS was an independent predictor of poorer outcomes, including composite cardiovascular events (hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.80–3.09; P<0.001), ACD (HR, 2.04; 95% CI, 1.47–2.84; P<0.001), and HF hospitalization (HR, 2.36; 95% CI, 1.81–3.09; P<0.001) (Table 3). Other independent predictors of composite cardiovascular events included older age, lower BMI, and lower systolic blood pressure. We also performed a sensitivity analysis adjusting for AF duration, given that a large proportion of patients in this AFMR cohort had AF; however, AF duration was not identified as a significant prognostic factor, and the association between CRAS and outcomes remained unchanged. Table 3.Potential Risk Factors for ACD and HF Admission ACD or HF hospitalizationACDHF hospitalizationHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueCRAS2.36 (1.80–3.09)<0.0012.04 (1.47–2.84)<0.0012.36 (1.81–3.09)<0.001Age1.03 (1.02–1.06)<0.0011.04 (1.02–1.06)<0.0011.04 (1.02–1.06)<0.001BMI0.95 (0.91–0.99)0.0100.92 (0.87–0.97)<0.0010.95 (0.91–0.99)0.010SBP0.99 (0.98–0.99)0.0300.99 (0.98–0.99)0.0430.99 (0.99–1.00)0.030Male sex1.25 (0.97–1.60)0.0851.63 (1.20–2.22)0.0021.25 (0.97–1.60)0.085MR severity1.20 (0.86–1.66)0.2761.10 (0.73–1.64)0.6581.20 (0.87–1.67)0.276EuroSCORE II1.01 (0.99–1.03)0.2511.03 (1.00–1.04)0.0651.01 (0.99–1.03)0.251Multivariable Cox proportional hazards models included 901 patients with complete data for all covariates. Among 957 patients, data for BMI and SBP were missing for 5 and 52 patients, respectively, while data for all other covariates were available for all patients. ACD, all-cause death; CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1. Table 3.Potential Risk Factors for ACD and HF Admission ACD or HF hospitalizationACDHF hospitalizationHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueCRAS2.36 (1.80–3.09)<0.0012.04 (1.47–2.84)<0.0012.36 (1.81–3.09)<0.001Age1.03 (1.02–1.06)<0.0011.04 (1.02–1.06)<0.0011.04 (1.02–1.06)<0.001BMI0.95 (0.91–0.99)0.0100.92 (0.87–0.97)<0.0010.95 (0.91–0.99)0.010SBP0.99 (0.98–0.99)0.0300.99 (0.98–0.99)0.0430.99 (0.99–1.00)0.030Male sex1.25 (0.97–1.60)0.0851.63 (1.20–2.22)0.0021.25 (0.97–1.60)0.085MR severity1.20 (0.86–1.66)0.2761.10 (0.73–1.64)0.6581.20 (0.87–1.67)0.276EuroSCORE II1.01 (0.99–1.03)0.2511.03 (1.00–1.04)0.0651.01 (0.99–1.03)0.251Multivariable Cox proportional hazards models included 901 patients with complete data for all covariates. Among 957 patients, data for BMI and SBP were missing for 5 and 52 patients, respectively, while data for all other covariates were available for all patients. ACD, all-cause death; CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1. Potential Risk Factors for ACD and HF Admission Multivariable Cox proportional hazards models included 901 patients with complete data for all covariates. Among 957 patients, data for BMI and SBP were missing for 5 and 52 patients, respectively, while data for all other covariates were available for all patients. ACD, all-cause death; CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1. Interaction of CRAS Components Interaction analysis of CRAS components showed that HF (HR, 2.29; 95% CI, 1.12–5.34; P=0.023) and anemia (HR, 2.41; 95% CI, 1.01–6.09; P=0.047) were independently associated with poorer outcomes, but CKD alone was not statistically significance (HR, 1.98; 95% CI, 0.53–6.33; P=0.287) (Table 4). None of the interaction terms for the 2-component combinations (HF + CKD, HF + anemia, CKD + anemia), or for CRAS overall, were statistically significant, indicating no synergistic interaction. Table 4.Evaluation of Interactions Among CRAS Components ACD or HF hospitalizationHR (95% CI)P valueAge1.03 (1.02–1.05)<0.001BMI0.95 (0.92–0.99)0.022SBP0.99 (0.99–1.00)0.052Male1.20 (0.93–1.55)0.156MR severity1.14 (0.81–1.57)0.446EuroSCORE II1.01 (0.99–1.03)0.325HF2.29 (1.12–5.34)0.023CKD1.98 (0.53–6.33)0.287Anemia2.41 (1.01–6.09)0.047HF + CKD0.49 (0.13–2.04)0.308HF + anemia0.56 (0.20–1.48)0.243CKD + anemia0.86 (0.22–3.85)0.839CRAS2.30 (0.45–10.54)0.304In total, 901 patients with complete data for all covariates were included. Among 957 patients, data for BMI and SBP were missing for 5 and 52 patients, respectively; data for all other covariates were available for all patients. CKD, chronic kidney disease. Other abbreviations as in Tables 1,3. Table 4.Evaluation of Interactions Among CRAS Components ACD or HF hospitalizationHR (95% CI)P valueAge1.03 (1.02–1.05)<0.001BMI0.95 (0.92–0.99)0.022SBP0.99 (0.99–1.00)0.052Male1.20 (0.93–1.55)0.156MR severity1.14 (0.81–1.57)0.446EuroSCORE II1.01 (0.99–1.03)0.325HF2.29 (1.12–5.34)0.023CKD1.98 (0.53–6.33)0.287Anemia2.41 (1.01–6.09)0.047HF + CKD0.49 (0.13–2.04)0.308HF + anemia0.56 (0.20–1.48)0.243CKD + anemia0.86 (0.22–3.85)0.839CRAS2.30 (0.45–10.54)0.304In total, 901 patients with complete data for all covariates were included. Among 957 patients, data for BMI and SBP were missing for 5 and 52 patients, respectively; data for all other covariates were available for all patients. CKD, chronic kidney disease. Other abbreviations as in Tables 1,3. Evaluation of Interactions Among CRAS Components In total, 901 patients with complete data for all covariates were included. Among 957 patients, data for BMI and SBP were missing for 5 and 52 patients, respectively; data for all other covariates were available for all patients. CKD, chronic kidney disease. Other abbreviations as in Tables 1,3. Discussion In this national, real-world cohort from the REVEAL-AFMR registry, the main findings were as follows: (1) approximately 25% of patients with AFMR had CRAS; (2) the prevalence of CRAS and its individual components increased with greater MR severity; and (3) CRAS independently predicted higher rates of future cardiovascular events, including ACD and HF hospitalization. Interaction analysis showed that HF and anemia contributed to poor cardiovascular outcomes and had an additive effect on overall prognosis, but no statistical synergy among CRAS components was observed, indicating that CRAS represents a clinically cumulative risk burden rather than a multiplicative interaction. These findings highlight the combined impact of HF, CKD, and anemia in patients with AFMR and emphasize the need for comprehensive risk assessment and integrated management. Mechanism of CRAS and the Association of AFMR Silverberg et al. first described the term CRAS in 2002 as the coexistence of chronic HF, CKD, and anemia.9 Each component reflects systemic organ dysfunction and exacerbates the others through interrelated pathophysiological mechanisms.10 First, HF reduces renal perfusion and triggers neurohormonal activation, thereby impairing kidney function. Second, kidney dysfunction activates the renin–angiotensin–aldosterone system, leading to fluid retention, myocardial hypertrophy, necrosis, and fibrosis, thereby worsening HF. Kidney dysfunction also suppresses erythropoietin production, leading to decreased erythrocyte production in the bone marrow, uremic toxin accumulation, and anemia. Finally, anemia further compromises oxygen delivery to peripheral tissues, activates the sympathetic nervous system, and increases cardiac workload, thereby accelerating left ventricular remodeling and HF progression. This vicious cycle creates synergistic deterioration and is strongly associated with adverse clinical outcomes. In the context of AFMR, CRAS may exert deleterious effects on a specific hemodynamic status. Elevated LA pressure, chronic venous congestion, and reduced forward cardiac output may have detrimental effects on renal function and anemia. In our study, the prevalence of overlapping conditions was as follows: HF and CKD in 332 (34.7%) patients, HF and anemia in 422 (44.1%), CKD and anemia in 288 (30.1%), and CRAS in 243 (25.4%) (Central Figure). HF, CKD, and anemia are often observed in patients with AFMR. With increasing MR severity, LAVI and TR velocity were elevated (Table 2), and the prevalence of CRAS and each of its individual components also increased (Figure 2). CRAS and Prognosis CRAS predicts poorer outcomes across various cardiovascular settings. In both acute and chronic HF, regardless of left ventricular ejection fraction, CRAS is associated with higher rates of hospitalization and death, with a reported prevalence of 19–62% and mortality rate as high as 51%.21–26 CRAS is also associated with poor prognosis in patients at risk for HF,27 those with acute myocardial infarction,28 and those with cancer.29 In MR, renal dysfunction30 and anemia31 have been associated with poor prognosis after transcatheter mitral valve repair; however, their prognostic relevance in the context of coexisting CRAS has not yet been fully elucidated. Similarly, in patients with AF, which is frequently observed in AFMR, HF,32 CKD,33 and anemia34 have been reported as adverse prognostic factors, but the prognostic impact of CRAS remains unclear. To our knowledge, this is the first study to investigate the prognostic value of CRAS in patients with AFMR. We found that each component of CRAS (i.e., HF, CKD, and anemia) was individually associated with adverse outcomes in patients with AFMR. The coexistence of these conditions in CRAS exerted an additional adverse effect on prognosis, worsening clinical outcomes beyond those associated with any single component. This association between CRAS and adverse clinical outcomes remained consistent regardless of the severity of MR or treatment strategy. Therefore, CRAS represents a key risk factor in patients with AFMR and warrants comprehensive evaluation and management. Clinical Implications Our findings highlight the potential benefits of targeting CRAS components, particularly HF and anemia, in the management of patients with AFMR. Because effective strategies to improve prognosis in AFMR remain poorly defined, clarifying the role of modifiable factors such as CRAS is clinically important. According to current clinical guidelines, surgical or transcatheter mitral valve intervention is recommended for patients with symptomatic severe AFMR despite optimization of medical therapy.35,36 In this context, management for CRAS may represent an important component of medical optimization prior to mitral valve intervention. In addition, in our cohort, CRAS remained a prognostic factor even among patients who underwent surgical or transcatheter treatment, indicating that continued management of CRAS both before and after mitral valve intervention may be important. Notably, the prevalence of CRAS components increased with greater AFMR severity, suggesting that patients with more advanced AFMR may require closer monitoring for the development or progression of renal dysfunction and anemia. Although data on the population with AFMR are limited, recent advances in HF management offer potential avenues for improving outcomes in patients with CRAS. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) increase hematocrit levels and alleviate anemia, in addition to improving prognosis in patients with HF and CKD.37 Recent studies have also reported potential effects of SGLT2i on LA remodeling, reduction in AF burden, and improvement in MR severity.4 Similarly, timely rhythm control or structural interventions for AFMR may interrupt the cycle of hemodynamic deterioration in patients with CRAS. In AF patients with moderate-to-severe AFMR undergoing catheter ablation, a shorter AF duration and less advanced LA remodeling are associated with greater reductions in LA size and improvements in MR, together with lower rates of AF recurrence, suggesting that early catheter ablation may contribute to improved clinical outcomes.38 The management of anemia and iron deficiency in patients with HF has garnered increasing attention in recent years, and treatment with intravenous iron has improved clinical outcomes.8,39–41 Conversely, the role of erythropoiesis-stimulating agents in renal anemia remains controversial,42–45 and evidence for hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors is still emerging; early studies, however, suggest potential benefits.46 The current clinical guidelines do not provide specific evidence-based recommendations for the management of patients with AFMR and CRAS. Nevertheless, early identification of and intervention for CRAS, including volume optimization, anemia correction, and renal protection, should form the cornerstone of treatment for this high-risk group. Future prospective studies are warranted to clarify optimal management strategies and improve outcomes. Study Limitations First, this was an observational registry study involving a heterogeneous patient population. Although treatment strategies were generally based on relevant Japanese clinical guideline,47 no standardized treatment protocols were used across the participating centers, which may have affected patient outcomes, including the indications and timing for surgical or transcatheter mitral valve repair. In addition, it was not possible to assess whether patients were receiving specific anemia treatments, including iron supplementation, erythropoiesis-stimulating agents, and HIF-PH inhibitors, either at the time of enrollment or during the subsequent follow-up period. Furthermore, this study was conducted before SGLT2i became reimbursed and widely used for HF and CKD management in Japan. Therefore, differences in SGLT2i use may influence clinical outcomes in contemporary practice. Second, longitudinal changes in renal function, hemoglobin levels, MR severity, and treatment response were not investigated. Data were evaluated at the time of enrollment; however, subsequent changes may have influenced the prognosis. Third, the etiologies of renal dysfunction and anemia were not determined. Levels of iron, total iron-binding capacity, transferrin, transferrin saturation, reticulocytes, vitamin B12, red cell distribution width, red blood cell count, mean corpuscular volume, and mean corpuscular hemoglobin were unavailable. In addition, information regarding the presence of active malignancy, hematological diseases, or bleeding disorders was not available. Prognostic differences based on the underlying causes of anemia and CKD may also be important and should be investigated in future studies. Fourth, although HF was defined primarily by symptomatic criteria reflecting current clinical guidelines, the absence of objective assessments, such as physical findings, may have led to an underestimation of HF. Finally, patients with ventricular functional MR or degenerative MR were not included in this study. Therefore, whether the prevalence and prognostic impact of CRAS differ between AFMR and other MR mechanisms remains uncertain. Despite these limitations, CRAS remained a significant risk factor for future cardiovascular events in patients with AFMR. Conclusions CRAS is common in patients with AFMR and independently associated with a high risk of future cardiovascular events. The results of our study emphasize the need for early recognition and comprehensive management of CRAS in this population. Further prospective investigations are warranted to determine whether targeted interventions against CRAS components can improve outcomes in patients with AFMR. Declaration of Interest N.K. received research grants from EchoNous Inc., AMI Inc., and AstraZeneca, and speaker honoraria from Eli Lilly, Novartis, Otsuka Pharmaceutical, and Nippon Boehringer Ingelheim outside of this work. He is affiliated with a department funded by Paramount Bed Ltd. M.O. received research grants from the Fukuda Foundation for Medical Technology, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Nippon Shinyaku, Takeda Science Foundation, Japanese Circulation Society, Japanese College of Cardiology, JSPS KAKENHI (21K16078), AMED (23jm0210104 h0002), AMI Inc., Boehringer Ingelheim, and Janssen; and speaker honoraria from AstraZeneca, Eli Lilly, Novartis, Otsuka Pharmaceutical, and Boehringer Ingelheim. K.S. belongs to an endowed department funded by Medtronic and DVX. T.K. received a research grant from the Japanese Circulation Society. Y.F. received speaker honoraria from Daiichi Sankyo and Bayer. Y.O. is a clinical proctor of transcatheter edge-to-edge repair for Abbott Medical and has received speaker fees from the company. The remaining authors have no conflicts of interest to disclose regarding this manuscript. IRB Information This study has been registered in the University Hospital Medical Information Network Clinical Trials Registry and the Japanese Clinical Trial Registry (registration number: UMIN000046146) and approved by the Institutional Review Board of Juntendo University and each participating institution, including Kobe City Medical Center General Hospital (approval number: kzh250408). Supplementary Files Supplementary Figure 1. Supplementary Figure 2. Supplementary Table.